News

The approval is based on positive data from the Phase III VIVID-DME and VISTA-DME trials and one open label single arm safety trial in Japanese patients (VIVID-Japan). During

Both the firms have not been disclosed financial details of the agreement. Aspen has agreed to specific annual commercial goals for Brinavess. Cardiome chief commercial officer Karim Lalji

The randomized, observer-blinded, dose-ranging trial will evaluate the safety and immunogenicity of the Seasonal Influenza VLP in 400 healthy adult subjects. The trial’s primary outcomes will be to

This announcement follows the successful testing of DCR-PH1 in combination with Tekmira’s LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay

KTE-C19 is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient’s T cells to express a CAR that is designed to target CD19, a protein

Licensing provides RetroSense with worldwide access to key intellectual property which reinforces the Company’s dominant position in optogenetics for vision restoration. The licensed intellectual property is based on

Dr. Gareth Lavery, a prominent researcher with the University of Birmingham’s Centre for Endocrinology, Diabetes and Metabolism (CEDAM), has been awarded a prestigious Senior Fellowship in Basic Biomedical

The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted

Teva’s Celecoxib is also indicated for the short-term management of moderate to severe acute pain in adults, in conditions such as musculoskeletal and/or soft tissue trauma including sprains,